Evidence map›Paper›PMID 40805991›Full record

ArticleNutrients2025

Trans-Sodium Crocetinate Ameliorates High-Altitude Acute Lung Injury via Modulating EGFR/PI3K/AKT/NF-κB Signaling Axis.

Keke Liang, Yanlin Ta, Liang Xu, Shuhe Ma, Renjie Wang, Chenrong Xiao, Yue Gao, Maoxing Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Keke LiangCollege of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730013, China.ORCID 0009-0001-5799-0231
Yanlin TaCollege of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730013, China.
Liang XuCollege of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730013, China.
Shuhe MaCollege of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730013, China.
Renjie WangCollege of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730013, China.
Chenrong XiaoDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Yue GaoDepartment of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing 100850, China.
Maoxing LiCollege of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730013, China.

Funding

The Outstanding Doctoral Student Project of Gansu Province 25JRRA258The Traditional Chinese Medicine Innovation Team and Talent Support Program Project from National Administration of Traditional Chinese Medicine ZYYCXTDD-202207
6 · The paper itself

Abstract

objectives

methodsThis study integrates network pharmacology with in vivo and in vitro validation to elucidate the molecular targets and mechanisms underlying TSC's therapeutic effects against high-altitude acute lung injury (HALI), aiming to identify novel treatment strategies.

resultsTSC effectively reversed hypoxia-induced biochemical abnormalities, ameliorated lung histopathological damage, and suppressed systemic inflammation and oxidative stress in HALI rats. In vitro, TSC mitigated CoCl

conclusionsTSC alleviates high-altitude hypoxia-induced lung injury by inhibiting the EGFR/PI3K/AKT/NF-κB signaling pathway, thereby attenuating inflammatory responses, oxidative stress, and restoring mitochondrial function. These findings highlight TSC as a promising therapeutic agent for HALI.

Indexed as

Acute Lung InjuryAltitude SicknessCarotenoidsProto-Oncogene Proteins c-aktSignal TransductionVitamin AAltitudeAnimalsDisease Models, AnimalErbB ReceptorsHumansLungMaleNetwork PharmacologyNF-kappa BOxidative StressCarotenoidsErbB ReceptorsNF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akttrans-sodium crocetinateVitamin AEGFR/PI3K/AKT/NF-κB signaling pathwayhigh-altitude acute lung injurymolecular dynamics simulationnetwork pharmacologytrans-sodium crocetinate

Identifiers

PMID40805991
PMCPMC12348565

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.